Compare UDR & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UDR | RGEN |
|---|---|---|
| Founded | 1972 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 11.0B |
| IPO Year | 1994 | 1995 |
| Metric | UDR | RGEN |
|---|---|---|
| Price | $36.22 | $176.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 22 |
| Target Price | $40.45 | ★ $197.95 |
| AVG Volume (30 Days) | ★ 3.7M | 1.2M |
| Earning Date | 11-02-2026 | 10-27-2026 |
| Dividend Yield | ★ 4.97% | N/A |
| EPS Growth | ★ 334.62 | 286.96 |
| EPS | ★ 0.57 | 0.24 |
| Revenue | ★ $1,712,317,000.00 | $141,236,000.00 |
| Revenue This Year | N/A | $12.87 |
| Revenue Next Year | $2.65 | $29.67 |
| P/E Ratio | ★ $61.50 | $750.67 |
| Revenue Growth | 2.42 | ★ 35.10 |
| 52 Week Low | $32.94 | $100.99 |
| 52 Week High | $42.00 | $198.87 |
| Indicator | UDR | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 67.80 | 49.30 |
| Support Level | $33.52 | $158.62 |
| Resistance Level | $38.38 | $188.73 |
| Average True Range (ATR) | 0.65 | 9.30 |
| MACD | 0.33 | -0.36 |
| Stochastic Oscillator | 93.67 | 51.66 |
UDR Inc is a real estate investment trust that owns, operates, acquires, renovates, develops, redevelops, disposes of, and manages multifamily apartment communities in targeted markets located in the United States. The company has two reportable segments; Same-Store Communities segment represents those communities acquired, developed, and stabilized; and Non-Mature Communities/Other segment represents those communities that do not meet the criteria to be included in Same-Store Communities, including, but not limited to, recently acquired, developed and redeveloped communities, and the non-apartment components of mixed-use properties. It generates key revenue from Same-Store Communities.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.